Form 4: Paula Soteropoulos Acquires Stock Options in Dianthus Therapeutics

Director Paula Soteropoulos reports acquisition of stock options in Dianthus Therapeutics.

Summary

• Paula Soteropoulos, a director of Dianthus Therapeutics, Inc., filed a Form 4 on May 22, 2025.
• The filing reports the acquisition of stock options to purchase 12,500 shares of Dianthus Therapeutics common stock.
• The exercise price of the stock options is $18.36.
• The options vest on the earlier of the first anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continued service.
• The options expire on May 22, 2035.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding stock option grants, indicating a neutral sentiment.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to incentivize their directors and officers.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term value creation.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment to the company's success.

Key Dates

Keywords

Form 4, Dianthus Therapeutics, Stock Options, Beneficial Ownership, Director, Soteropoulos, DNTH